UTHR
Income statement / Annual
Last year (2023), United Therapeutics Corporation's total revenue was $2.33 B,
an increase of 20.20% from the previous year.
In 2023, United Therapeutics Corporation's net income was $984.80 M.
See United Therapeutics Corporation’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$2.33 B
|
$1.94 B
|
$1.69 B
|
$1.48 B
|
$1.45 B
|
$1.63 B
|
$1.73 B
|
$1.60 B
|
$1.47 B
|
$1.29 B
|
| Cost of Revenue |
$257.50 M |
$146.70 M |
$122.50 M |
$108.10 M |
$117.60 M |
$198.70 M |
$105.70 M |
$72.70 M |
$69.04 M |
$125.88 M |
| Gross Profit |
$2.07 B |
$1.79 B |
$1.56 B |
$1.38 B |
$1.33 B |
$1.43 B |
$1.62 B |
$1.53 B |
$1.40 B |
$1.16 B |
| Gross Profit Ratio |
0.89 |
0.92 |
0.93 |
0.93 |
0.92 |
0.88 |
0.94 |
0.95 |
0.95 |
0.9 |
| Research and Development
Expenses |
$408.00 M
|
$322.90 M
|
$540.10 M
|
$357.70 M
|
$1.18 B
|
$357.90 M
|
$264.60 M
|
$147.60 M
|
$245.10 M
|
$242.55 M
|
| General & Administrative
Expenses |
$395.30 M
|
$416.20 M
|
$402.60 M
|
$369.00 M
|
$275.50 M
|
$206.70 M
|
$265.80 M
|
$232.20 M
|
$358.32 M
|
$299.29 M
|
| Selling & Marketing
Expenses |
$81.80 M
|
$70.80 M
|
$64.40 M
|
$54.90 M
|
$60.70 M
|
$59.10 M
|
$64.30 M
|
$84.60 M
|
$94.30 M
|
$82.00 M
|
| Selling, General &
Administrative Expenses |
$477.10 M
|
$487.00 M
|
$467.00 M
|
$423.90 M
|
$336.20 M
|
$265.80 M
|
$330.10 M
|
$316.80 M
|
$452.61 M
|
$381.29 M
|
| Other Expenses |
$0.00 |
-$40.20 M |
$42.20 M |
$49.30 M |
$22.60 M |
-$7.70 M |
$13.20 M |
$2.40 M |
$157,000.00 |
$3.97 M |
| Operating Expenses |
$885.10 M |
$809.90 M |
$1.01 B |
$781.60 M |
$1.52 B |
$623.70 M |
$594.70 M |
$464.40 M |
$697.71 M |
$623.84 M |
| Cost And Expenses |
$1.14 B |
$956.60 M |
$1.13 B |
$889.70 M |
$1.64 B |
$822.40 M |
$700.40 M |
$537.10 M |
$766.75 M |
$749.72 M |
| Interest Income |
$162.70 M |
$45.20 M |
$16.70 M |
$28.60 M |
$44.20 M |
$28.60 M |
$10.90 M |
$3.50 M |
$0.00 |
$0.00 |
| Interest Expense |
$59.30 M |
$32.40 M |
$18.60 M |
$23.50 M |
$44.20 M |
$13.90 M |
$9.00 M |
$3.90 M |
$4.74 M |
$17.59 M |
| Depreciation &
Amortization |
$53.20 M
|
$51.30 M
|
$49.90 M
|
$49.90 M
|
$45.90 M
|
$35.90 M
|
$31.00 M
|
$31.60 M
|
$32.92 M
|
$32.25 M
|
| EBITDA |
$1.39 B
|
$1.04 B
|
$736.80 M
|
$646.30 M
|
-$74.90 M
|
$838.40 M
|
$1.05 B
|
$1.09 B
|
$1.08 B
|
$575.02 M
|
| EBITDA Ratio |
0.6 |
0.51 |
0.36 |
0.45 |
-0.08 |
0.51 |
0.6 |
0.67 |
0.48 |
0.42 |
| Operating Income Ratio
|
0.51
|
0.51
|
0.33
|
0.4
|
-0.13
|
0.49
|
0.47
|
0.66
|
0.48
|
0.42
|
| Total Other
Income/Expenses Net |
$89.40 M
|
-$29.10 M
|
$38.00 M
|
$45.30 M
|
$22.60 M
|
-$46.50 M
|
-$45.40 M
|
-$1.50 M
|
$345.42 M
|
-$13.60 M
|
| Income Before Tax |
$1.27 B |
$950.60 M |
$593.90 M |
$638.90 M |
-$165.00 M |
$758.90 M |
$769.50 M |
$1.06 B |
$1.04 B |
$525.18 M |
| Income Before Tax Ratio
|
0.55
|
0.49
|
0.35
|
0.43
|
-0.11
|
0.47
|
0.45
|
0.66
|
0.71
|
0.41
|
| Income Tax Expense |
$289.50 M |
$223.30 M |
$118.10 M |
$124.10 M |
-$60.50 M |
$169.70 M |
$351.60 M |
$346.50 M |
$392.80 M |
$185.11 M |
| Net Income |
$984.80 M |
$727.30 M |
$475.80 M |
$514.80 M |
-$104.50 M |
$589.20 M |
$417.90 M |
$713.70 M |
$651.64 M |
$340.07 M |
| Net Income Ratio |
0.42 |
0.38 |
0.28 |
0.35 |
-0.07 |
0.36 |
0.24 |
0.45 |
0.44 |
0.26 |
| EPS |
21.04 |
15.98 |
10.6 |
11.65 |
-2.39 |
13.54 |
9.5 |
16.29 |
14.17 |
7.06 |
| EPS Diluted |
19.81 |
15 |
10.06 |
11.54 |
-2.39 |
13.39 |
9.31 |
15.25 |
12.72 |
6.28 |
| Weighted Average Shares
Out |
$46.80 M
|
$45.50 M
|
$44.90 M
|
$44.20 M
|
$43.80 M
|
$43.50 M
|
$44.00 M
|
$43.80 M
|
$46.00 M
|
$48.18 M
|
| Weighted Average Shares
Out Diluted |
$49.70 M
|
$48.50 M
|
$47.30 M
|
$44.60 M
|
$43.80 M
|
$44.00 M
|
$44.90 M
|
$46.80 M
|
$51.22 M
|
$54.16 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
